Teriparatide vs Abaloparatide for Osteoporosis
Bone Peptides
86% Vertebral Fracture Reduction
Abaloparatide reduced new vertebral fractures by 86% versus placebo in the ACTIVE trial, with teriparatide as an active comparator showing similar vertebral protection.
Miller et al., JAMA, 2016
Miller et al., JAMA, 2016
View as imageTwo injectable peptide drugs can build new bone in patients with osteoporosis: teriparatide (Forteo, approved 2002) and abaloparatide (Tymlos, approved 2017). Both work through the parathyroid hormone type 1 receptor (PTH1R), but they bind the receptor differently, produce different patterns of bone mineral density gain, and carry different side effect profiles. Miller et al. (2016) published the pivotal ACTIVE trial in JAMA, the first head-to-head comparison of the two drugs, finding that abaloparatide reduced new vertebral fractures by 86% versus placebo and showed a favorable hypercalcemia profile compared to the teriparatide arm.[1] For a broader overview of bone peptide drugs, see abaloparatide: the newer PTH analog for osteoporosis.
Key Takeaways
- In the ACTIVE trial, abaloparatide reduced vertebral fractures by 86% and nonvertebral fractures by 43% vs placebo over 18 months (Miller et al., 2016)[1]
- Miller et al. (2019) found BMD response rates were greater with abaloparatide: 76% of patients achieved >3% total hip BMD gain vs 50% with teriparatide[2]
- Hong et al. (2023) meta-analysis confirmed abaloparatide produces significantly greater BMD increases at the total hip and femoral neck than teriparatide[3]
- Hypercalcemia occurred in 3.4% of abaloparatide patients vs 6.4% with teriparatide in the ACTIVE trial[1]
- Both drugs act through PTH1R but bind different receptor conformations: abaloparatide prefers the RG (transient) state, teriparatide the R0 (prolonged) state (Sato et al., 2021)[4]
- Sequential therapy with alendronate after abaloparatide maintained BMD gains and further reduced fractures over 43 months total (Bone et al., 2018)[5]
How They Differ at the Receptor Level
Both teriparatide and abaloparatide activate PTH1R, but they do so differently. The PTH1 receptor exists in two conformational states: R0 (a stable conformation that produces prolonged signaling) and RG (a G-protein-coupled conformation that produces transient signaling).
Sato et al. (2021) investigated the intracellular signaling pathways activated by teriparatide, abaloparatide, and a long-acting PTH variant. All three ligands engaged the same initial signaling cascades (cAMP, ERK1/2, beta-arrestin recruitment), but their binding kinetics differed. Abaloparatide preferentially binds the RG conformation, producing a shorter burst of cAMP signaling. Teriparatide binds both R0 and RG conformations, resulting in more sustained cAMP elevation.[4]
This distinction matters for bone biology. Prolonged PTH1R activation (the R0 pattern associated with teriparatide) stimulates both bone formation and bone resorption. Transient activation (the RG pattern associated with abaloparatide) favors bone formation with less stimulation of resorption. The net result: abaloparatide may produce a more favorable "anabolic window" where new bone is being built faster than old bone is being broken down, particularly at cortical bone sites like the hip. For the broader biology of why intermittent PTH stimulation builds bone while continuous exposure destroys it, see parathyroid hormone and bone.
Miller et al. (2020) reviewed the full pharmacological profile of abaloparatide, emphasizing that both drugs activate osteoblasts (bone-building cells) through cAMP/PKA signaling, but the duration of receptor occupancy affects the ratio of osteoblast to osteoclast stimulation. When PTH1R signaling is brief and pulsatile, osteoblast activation predominates. When signaling is sustained, osteoclast recruitment increases through RANKL upregulation. Abaloparatide's faster receptor dissociation kinetics tilt this balance more consistently toward the anabolic side.[11] For a detailed look at teriparatide's pharmacology, see teriparatide (Forteo): the parathyroid hormone peptide that builds bone.
The ACTIVE Trial: Head-to-Head Data
The Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) was the definitive comparison study. Miller et al. (2016) randomized 2,463 postmenopausal women with osteoporosis to one of three arms: abaloparatide 80 mcg/day, teriparatide 20 mcg/day, or placebo, all given by daily subcutaneous injection for 18 months.[1]
Fracture Results
| Outcome | Abaloparatide vs Placebo | Teriparatide vs Placebo |
|---|---|---|
| New vertebral fractures | 86% reduction | 80% reduction |
| Nonvertebral fractures | 43% reduction | 28% reduction |
| Clinical fractures | 43% reduction | Not significant |
| Major osteoporotic fractures | 70% reduction | 55% reduction |
Both drugs reduced vertebral fractures substantially. The numerical advantage of abaloparatide for nonvertebral and clinical fractures did not reach statistical significance in the direct abaloparatide-versus-teriparatide comparison because the trial was powered for placebo comparison, not a head-to-head test between active drugs.
BMD Changes
Miller et al. (2019) analyzed BMD response rates from ACTIVE in greater detail. At 18 months, mean BMD increases were:[2]
- Lumbar spine: abaloparatide +11.2%, teriparatide +10.5%
- Total hip: abaloparatide +4.2%, teriparatide +3.3%
- Femoral neck: abaloparatide +3.6%, teriparatide +2.6%
The hip and femoral neck differences were statistically significant in favor of abaloparatide. The lumbar spine differences were not significant. Using a clinically meaningful threshold of >3% BMD gain at the total hip, 76% of abaloparatide patients achieved this target versus 50% with teriparatide.
Hypercalcemia
Teriparatide's more sustained PTH1R activation also stimulates calcium release from bone. In ACTIVE, hypercalcemia (serum calcium >10.7 mg/dL) occurred in 3.4% of the abaloparatide group versus 6.4% of the teriparatide group. This approximately 2-fold difference is consistent with abaloparatide's preferential binding to the transient RG conformation.
The Meta-Analysis Confirmation
Hong et al. (2023) published an updated meta-analysis comparing abaloparatide and teriparatide across all available studies. The analysis confirmed that abaloparatide produces significantly greater BMD increases at the total hip and femoral neck than teriparatide, while lumbar spine gains are comparable. Abaloparatide also showed a nonsignificantly lower risk of adverse events overall.[3]
The meta-analysis strengthened the conclusion that abaloparatide's advantage is site-specific: it outperforms teriparatide at cortical bone sites (hip, femoral neck) but not at trabecular bone sites (lumbar spine). This pattern is consistent with the receptor pharmacology: the transient RG signaling associated with abaloparatide may preferentially stimulate cortical bone formation while producing less cortical bone resorption.
Sequential Therapy: What Comes After
Both drugs carry a maximum treatment duration of 2 years (24 months for teriparatide, labeled for 18 months for abaloparatide in clinical trials). Bone gained during anabolic therapy is lost rapidly if treatment is stopped without transition to an anti-resorptive drug.
Bone et al. (2018) published the ACTIVExtend results: 24 months of alendronate following 18 months of abaloparatide or placebo. The abaloparatide-to-alendronate sequence maintained and extended BMD gains at all sites. Over the combined 43-month period, the abaloparatide/alendronate group showed a 84% reduction in vertebral fractures and sustained nonvertebral fracture protection compared to the placebo/alendronate group.[5]
Cosman et al. (2017) reported the earlier 6-month alendronate follow-up data, showing that BMD continued to increase at the hip and spine during the alendronate phase after abaloparatide, rather than simply maintaining the gains.[6] This suggests that the bone laid down during abaloparatide treatment is not only preserved but continues to mineralize during subsequent anti-resorptive therapy. For context on how GLP-1s affect bone density during weight loss, the mechanisms differ substantially from anabolic bone therapies.
Specific Populations
Women Over 80
Greenspan et al. (2020) performed a post hoc analysis of ACTIVE/ACTIVExtend in women aged 80 years and older. In this high-risk subgroup, abaloparatide followed by alendronate increased lumbar spine BMD by 12.4% at 18 months and maintained gains during the alendronate phase. The fracture reduction was consistent with the overall trial results, and no new safety signals emerged in the older cohort.[7]
Men With Osteoporosis
Czerwinski et al. (2022) published the ATOM trial, the first randomized study of abaloparatide in men with osteoporosis. Over 12 months, abaloparatide increased lumbar spine BMD by 8.48% versus 1.17% with placebo. Total hip and femoral neck BMD also increased significantly. The safety profile was consistent with the ACTIVE trial in women.[8] Teriparatide has been available for men since 2002, so abaloparatide's approval in men expanded the options.
Dose-Response and Formulation
Leder et al. (2015) published the phase 2 dose-finding study for abaloparatide, testing doses of 20, 40, and 80 mcg/day in postmenopausal women. The 80 mcg dose produced the greatest BMD increases: 6.7% at the lumbar spine, 2.6% at the femoral neck, and 3.4% at the total hip over 24 weeks. This dose was selected for the phase 3 ACTIVE trial.[9]
Matsumoto et al. (2023) confirmed dose-dependent BMD increases with abaloparatide in a Japanese postmenopausal population, supporting the dose-response relationship across ethnicities.[10]
Both teriparatide and abaloparatide are currently available as daily subcutaneous injections. Miller et al. (2021) evaluated a solid microstructured transdermal system (sMTS patch) for abaloparatide delivery, which would eliminate the need for daily injections. The phase 1b study showed bioavailability comparable to subcutaneous injection, and development is ongoing.[11]
Side-by-Side Summary
| Feature | Teriparatide (Forteo) | Abaloparatide (Tymlos) |
|---|---|---|
| Molecule | PTH(1-34) fragment | PTHrP analog (34 aa) |
| Receptor binding | R0 + RG (prolonged) | RG preferred (transient) |
| Approved | 2002 | 2017 |
| Lumbar spine BMD (18 mo) | +10.5% | +11.2% |
| Total hip BMD (18 mo) | +3.3% | +4.2% |
| Femoral neck BMD (18 mo) | +2.6% | +3.6% |
| Hypercalcemia rate | 6.4% | 3.4% |
| Route | Daily SC injection | Daily SC injection |
| Max duration | 24 months | 18-24 months |
| Available for men | Yes | Yes (ATOM trial, 2022) |
| Biosimilar available | Yes (2023+) | No |
Limitations
The ACTIVE trial was not statistically powered for a head-to-head comparison between abaloparatide and teriparatide. It was designed to detect differences versus placebo, with teriparatide as a reference arm. The apparent advantages of abaloparatide in nonvertebral fracture reduction and hip BMD are real observations from the trial, but their statistical significance in direct comparison is limited by sample size.
The 18-month treatment window limits the total bone gain achievable with either drug. Both drugs lose their benefit if not followed by anti-resorptive therapy, making sequential treatment planning essential.
Long-term fracture data beyond 3-4 years (including the sequential therapy period) is limited. The ACTIVExtend trial followed patients for a total of approximately 43 months (18 months abaloparatide plus 24 months alendronate), which represents the longest available follow-up for the abaloparatide sequence. Teriparatide has more long-term observational data due to its 15-year head start.
Cost is a practical differentiator. Both drugs carry high list prices ($2,000-3,500/month in the US), but teriparatide now has biosimilar competition, which may lower costs. Abaloparatide has no biosimilar competitors.
Neither drug has been compared head-to-head with romosozumab (Evenity), the sclerostin antibody that builds bone through a different mechanism entirely. Network meta-analyses suggest all three anabolic agents outperform bisphosphonates for BMD gain, but direct comparison data between the newer agents is lacking. The choice between teriparatide, abaloparatide, and romosozumab often comes down to individual patient risk profiles and insurance coverage. For context on other peptide therapies for bone, see calcitonin: the bone-protecting peptide hormone. For research on peptides that may affect fracture healing, see BPC-157 and bone healing.
The Bottom Line
Teriparatide and abaloparatide both build bone through PTH1R activation but differ in receptor binding kinetics. Abaloparatide's preferential binding to the transient RG conformation produces greater BMD gains at the hip and femoral neck with lower hypercalcemia rates compared to teriparatide. Both drugs reduce vertebral fractures by 80-86% versus placebo. Sequential therapy with alendronate after either drug maintains and extends the gains. The ACTIVE trial provides the primary comparison data, though it was not powered for a direct head-to-head statistical comparison.